Clostridioides difficile infection (CDI) is one of the major issues in nosocomial infections.
This bacterium is constantly evolving and poses complex challenges for clinicians, often …

Methods: We performed a systematic review and meta-analysis to pool the rate of rCDI in
patients receiving BEZ and explore its efficacy and safety in preventing rCDI compared with …

Background Bezlotoxumab (BEZ) is a monoclonal antibody used to prevent recurrent
Clostridioides difficile infection (rCDI). This study investigates BEZ effectiveness in relation to …

Clostridioides difficile infections (CDIs), and particularly recurrent infections, cause a
significant burden on the health-care system. Bezlotoxumab is a new agent for the …

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals.
Despite the fact that CDI has treatment options, recurrence is common after the treatment …

Objectives: Approximately 25% of patients with Clostridioides difficile infection (CDI) will
experience recurrence, which is greater in immunocompromised patients. We report …

Antimicrobial stewardship is valuable to transplant programs to reduce the threat of
antimicrobial resistance, improve patient outcomes, and attenuate risks of drug toxicities. 1 …

Clostridium difficile infection (CDI) has been increasing due to the effect of recurrent
hospitalizations. The use of antibiotics has been shown to alter the gut microbiome and lead …

Background Clostridioides difficile infection (CDI) recurrence is a public health concern as
well as a health economic burden. Bezlotoxumab treatment is one way to prevent …

Goals and background Clostridium difficile infection (CDI) is the leading cause of antibiotic‐
associated diarrhea in the United States. We aimed to determine comparative trends in …